IκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinoma

IκB Kinase α is required for development and progression of KRAS-mutant lung adenocarcinoma

Although oncogenic activation of NFkB has been identified in various tumors, the NFkB–activating kinases (inhibitor of NFkB kinases, IKK) responsible for this are elusive. In this study, we determined the role of IKKa and IKKb in KRAS-mutant lung adenocarcinomas induced by the carcinogen urethane an...

Full description

Bibliographic Details
Main Authors:	Vreka, M, Lilis, I, Papageorgopoulou, M, Giotopoulou, G, Lianou, M, Giopanou, I, Kanellakis, N, Spella, M, Agalioti, T, Armenis, V, Goldmann, T, Marwitz, S, Yull, F, Blackwell, T, Pasparakis, M, Marazioti, A, Stathopoulos, G
Format:	Journal article
Language:	English
Published:	American Association for Cancer Research 2018

Similar Items

LSC Abstract – Host-environmental IL-1b drives mutant KRAS-IKKa addiction in malignant pleural effusion
by: Marazioti, A, et al.
Published: (2016)

Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma
by: Ioannis Lilis, et al.
Published: (2019-07-01)

Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion
by: Marazioti, A, et al.
Published: (2018)

NRAS destines tumor cells to the lungs
by: Giannou, AD, et al.
Published: (2017)

LSC - 2017 - CREB signaling in KRAS-driven lung adenocarcinoma
by: Giotopoulou, G, et al.
Published: (2017)

Myeloid-derived interleukin-1β drives oncogenic KRAS-NF-κΒ addiction in malignant pleural effusion
by: Antonia Marazioti, et al.
Published: (2018-02-01)

S7 Mouse lung adenocarcinoma cell lines reveal PRL2C2 as a novel lung tumour promoter
by: Kanellakis, N, et al.
Published: (2016)

cAMP-response element binding protein in KRAS-driven lung adenocarcinoma
by: Giotopoulou, G, et al.
Published: (2016)

Tumor-derived osteopontin isoforms cooperate with TRP53 and CCL2 to promote lung metastasis
by: Giopanou, I, et al.
Published: (2016)

Comprehensive Evaluation of Nuclear Factor-κΒ Expression Patterns in Non-Small Cell Lung Cancer.
by: Ioanna Giopanou, et al.
Published: (2015-01-01)

Mutant KRAS promotes malignant pleural effusion formation
by: Theodora Agalioti, et al.
Published: (2017-05-01)

Tumor cell-derived osteopontin promotes lung metastasis via both cell-autonomous and paracrine pathways
by: Kanellakis, N, et al.
Published: (2016)

Non-Oncogene Addiction of <i>KRAS</i>-Mutant Cancers to IL-1β via Versican and Mononuclear IKKβ
by: Magda Spella, et al.
Published: (2023-03-01)

Mutant KRAS promotes malignant pleural effusion formation
by: Αgalioti, T, et al.
Published: (2017)

S8 Osteopontin as an airway epithelial tumour promoter
by: Psallidas, I, et al.
Published: (2016)

LSC-2017-Mouse lung adenocarcinoma cell lines as tools to identify novel lung cancer genes
by: Kanellakis, N, et al.
Published: (2017)

LSC Abstract – Osteopontin as an airway epithelial tumor promoter
by: Psallidas, I, et al.
Published: (2016)

Club cells form lung adenocarcinomas and maintain the alveoli of adult mice
by: Spella, M, et al.
Published: (2019)

KRAS signaling in malignant pleural mesothelioma
by: Antonia Marazioti, et al.
Published: (2022-02-01)

An In Vivo Inflammatory Loop Potentiates KRAS Blockade
by: Kristina A. M. Arendt, et al.
Published: (2022-03-01)

RAS oncogenes direct metastasis
by: Magda Spella, et al.
Published: (2017-09-01)

Club cells form lung adenocarcinomas and maintain the alveoli of adult mice
by: Magda Spella, et al.
Published: (2019-05-01)

Shared epithelial pathways to lung repair and disease
by: Magda Spella, et al.
Published: (2017-06-01)

Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
by: Yuta Adachi, et al.
Published: (2021-10-01)

Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2019-04-01)

A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
by: Xiufeng Pang, et al.
Published: (2016-10-01)

Correction to: Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy
by: Ke Xu, et al.
Published: (2020-05-01)

Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.
by: Antonia Marazioti, et al.
Published: (2013-01-01)

A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS
by: Nicolas Bery, et al.
Published: (2020-06-01)

Small molecular inhibitors for KRAS-mutant cancers
by: Xuan Wu, et al.
Published: (2023-08-01)

In silico analysis of wild-type and mutant KRAS
by: Frengki Frengki, et al.
Published: (2019-05-01)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
by: Elisa Baldelli, et al.
Published: (2021-09-01)

Immune Resistance in Lung Adenocarcinoma
by: Magda Spella, et al.
Published: (2021-01-01)

KRAS mutant allele-specific expression knockdown in pancreatic cancer model with systemically delivered bi-shRNA KRAS lipoplex.
by: Donald D Rao, et al.
Published: (2018-01-01)

KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player
by: Lilith Trassl, et al.
Published: (2022-09-01)

Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers
by: Jimi Kim
Published: (2023-11-01)

Mutant KRAS-Associated Proteome Is Mainly Controlled by Exogenous Factors
by: Patrícia Dias Carvalho, et al.
Published: (2022-06-01)

KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
by: Daniel Zeitouni, et al.
Published: (2016-04-01)

Mutant KRAS Exosomes Influence the Metabolic State of the Colon Microenvironment
by: Ranjan Preet, PhD, et al.
Published: (2018-01-01)

Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy.
by: Xin Dai, et al.
Published: (2015-01-01)